These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36293227)

  • 1. Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients.
    Nötzel M; Werder LI; Ziemssen T; Akgün K
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of SIMOA and VEUS technologies for serum neurofilament light chain measurement in multiple sclerosis.
    Pelisek O; Kusnierova P; Hradilek P; Horakova J; Svub K; Siprova K; Sobek O; Ganesh A; Hanzlikova P; Volny O; Revendova KZ
    Mult Scler Relat Disord; 2024 Oct; 90():105815. PubMed ID: 39146894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels.
    Revendova KZ; Zeman D; Bunganic R; Karasova K; Volny O; Bar M; Kusnierova P
    Mult Scler Relat Disord; 2022 Nov; 67():104177. PubMed ID: 36130459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
    Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2024; 15():1454474. PubMed ID: 39224593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Simoa
    Gauthier A; Viel S; Perret M; Brocard G; Casey R; Lombard C; Laurent-Chabalier S; Debouverie M; Edan G; Vukusic S; Lebrun-Frénay C; De Sèze J; Laplaud DA; Castelnovo G; Gout O; Ruet A; Moreau T; Casez O; Clavelou P; Berger E; Zephir H; Trouillet-Assant S; Thouvenot E;
    Ann Clin Transl Neurol; 2021 May; 8(5):1141-1150. PubMed ID: 33830650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
    Kuhle J; Daizadeh N; Benkert P; Maceski A; Barro C; Michalak Z; Sormani MP; Godin J; Shankara S; Samad TA; Jacobs A; Chung L; Rӧsch N; Kaiser C; Mitchell CP; Leppert D; Havari E; Kappos L
    Mult Scler; 2022 Apr; 28(4):573-582. PubMed ID: 34378446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice.
    Valentino P; Marnetto F; Martire S; Malucchi S; Bava CI; Popovic M; Bertolotto A
    Mult Scler Relat Disord; 2021 Sep; 54():103090. PubMed ID: 34182224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH
    Mult Scler; 2020 Nov; 26(13):1670-1681. PubMed ID: 31610732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Srpova B; Uher T; Hrnciarova T; Barro C; Andelova M; Michalak Z; Vaneckova M; Krasensky J; Noskova L; Havrdova EK; Kuhle J; Horakova D
    Mult Scler; 2021 Jan; 27(1):52-60. PubMed ID: 31961243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Bsteh G; Berek K; Hegen H; Teuchner B; Buchmann A; Voortman MM; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Khalil M; Berger T
    Mult Scler; 2020 Nov; 26(13):1682-1690. PubMed ID: 31668116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
    J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients.
    Hänninen K; Jääskeläinen O; Herukka SK; Soilu-Hänninen M
    Brain Behav; 2020 Sep; 10(9):e01772. PubMed ID: 32705821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
    Seiberl M; Feige J; Hilpold P; Hitzl W; Machegger L; Buchmann A; Khalil M; Trinka E; Harrer A; Wipfler P; Moser T
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.
    Jakimovski D; Kuhle J; Ramanathan M; Barro C; Tomic D; Hagemeier J; Kropshofer H; Bergsland N; Leppert D; Dwyer MG; Michalak Z; Benedict RHB; Weinstock-Guttman B; Zivadinov R
    Ann Clin Transl Neurol; 2019 Sep; 6(9):1757-1770. PubMed ID: 31437387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study.
    Truffi M; Garofalo M; Ricciardi A; Cotta Ramusino M; Perini G; Scaranzin S; Gastaldi M; Albasini S; Costa A; Chiavetta V; Corsi F; Morasso C; Gagliardi S
    Sci Rep; 2023 Mar; 13(1):4041. PubMed ID: 36899015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients.
    Jakimovski D; Gibney BL; Marr K; Ramasamy DP; Dwyer MG; Bergsland N; Weinstock-Guttman B; Ramanathan M; Zivadinov R
    Eur J Neurol; 2022 Aug; 29(8):2299-2308. PubMed ID: 35474598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.